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Abstract
Background—Arsenic has immunomodulatory properties and may have the potential to alter 
susceptibility to infection in humans.
Objectives—We aimed to assess the relation of arsenic exposure during pregnancy with immune 
function and hepatitis E virus (HEV) infection, defined as seroconversion during pregnancy and 
postpartum.
Methods—We assessed IgG seroconversion to HEV between 1st and 3rd trimester (TM) and 3 
months postpartum (PP) among 1100 pregnancies in a multiple micronutrient supplementation 
trial in rural Bangladesh. Forty women seroconverted to HEV and were matched with 40 non-
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seroconverting women (controls) by age, parity and intervention. We assessed urinary inorganic 
arsenic plus methylated species (∑As) (µg/L) at 1st and 3rd TM and plasma cytokines (pg/mL) at 
1st and 3rd TM and 3 months PP.
Results—HEV seroconverters’ urinary ∑As was elevated throughout pregnancy. Non-
seroconverters’ urinary ∑As was similar to HEV seroconverters at 1st TM but declined at 3rd TM. 
The adjusted odds ratio (95% confidence interval) of HEV seroconversion was 2.17 (1.07, 4.39) 
per interquartile range (IQR) increase in average-pregnancy urinary ∑As. Increased urinary ∑As 
was associated with increased concentrations of IL-2 during the 1st and 3rd TM and 3 months PP 
among HEV seroconverters but not non-seroconverters.
Conclusions—The relation of urinary arsenic during pregnancy with incident HEV 
seroconversion and with IL-2 levels among HEV-seroconverting pregnant women suggests 
arsenic exposure during pregnancy may enhance susceptibility to HEV infection.
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1. Background
Arsenic represents a major threat to global health, with millions of people exposed through 
contaminated food and water, particularly in areas of the world where arsenic is naturally 
occurring in the environment (IARC, 2012). In Bangladesh, an estimated 45 million people 
are exposed to arsenic concentrations in drinking water greater than the World Health 
Organization (WHO) guideline value (10 µg/L) and 20 million people are exposed to 
concentrations greater than the Bangladeshi national standard (50 µg/L) (Flanagan et al., 
2012). A recognized toxicant (IARC, 2012) and carcinogen (IARC, 2012), arsenic has been 
related to increased risk of cardiovascular, lung, kidney, bladder, skin, prostate, and liver 
disease (IARC, 2012; Liu and Waalkes, 2008; Wu et al., 2014). Arsenic has also been linked 
to increased systemic inflammation via oxidative stress (Ahmed et al., 2011) and chronic 
metabolic disorders including diabetes (Navas-Acien et al., 2008). Appreciation of the 
immunotoxic effects of arsenic and its potential to alter immune function is emerging 
(Dangleben et al., 2013). Laboratory studies reveal that arsenic inhibits antigen-presentation 
of macrophages (Banerjee et al., 2009) and T cell proliferation (Soto-Pena and Vega, 2008), 
decreases CD4+ T cell numbers in the spleen (Sikorski et al., 1989), and suppresses contact 
hypersensitivity responses (Patterson et al., 2004). The ability of arsenic to alter 
susceptibility to infection by affecting immune response is becoming increasingly 
recognized (Bailey et al., 2013; Farzan et al., 2013b; Kozul et al., 2009; Rager et al., 2014).
Pregnancy represents a unique period of susceptibility to infection (Kourtis et al., 2014) in 
part because of a shift toward an anti-inflammatory immune response (Kraus et al., 2012) 
due to changes in estrogen and progesterone levels (Shelly et al., 2012). No studies, to our 
knowledge, have investigated the dynamics of specific objectively measured infections 
among pregnant women exposed to arsenic. One study among 140 pregnant women in 
Matlab, Bangladesh, showed that increasing urinary arsenic concentrations were associated 
with increasing frequency of self-reported days of fever and diarrhea during pregnancy 
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(Raqib et al., 2009). Though this study lacked objective measures of specific infections, its 
findings suggest a possible involvement of arsenic exposure in susceptibility to infection 
during pregnancy. Most attention has focused on the relation of in-utero arsenic exposure 
with the fetal immune repertoire (Nadeau et al., 2014) and infectious outcomes during early 
childhood (Farzan et al., 2013a,, 2013b; Rahman et al., 2011). Studies have also shown that 
in-utero and childhood arsenic exposure can alter vaccine immune responses in children 
(Ahmed et al., 2014; Saha et al., 2013). This emerging literature reflects a growing 
understanding of the immunomodulatory properties of arsenic; however, whether (and how) 
this affects susceptibility to specific infections in humans is not well understood.
Hepatitis E virus (HEV) is a non-enveloped positive-strand RNA virus, transmitted 
primarily via the fecal-oral route (e.g., contaminated surface water). HEV infection can be 
measured objectively via assessment of anti-HEV IgG seroconversion (Innis et al., 2002). 
Among individuals who seroconvert, HEV infection can be either asymptomatic or cause 
disease (hepatitis E) which is usually self-limited. However, some individuals with hepatitis 
E experience severe disease, known as acute fulminant hepatitis. HEV is a leading global 
cause of acute viral hepatitis (Mahtab et al., 2009; Rein et al., 2012) and causes significant 
morbidity and mortality during pregnancy (Labrique et al., 2012), particularly in South Asia 
where seasonal floods and poor sanitation have led to widespread contamination of surface 
water supplies with HEV and large epidemics of HEV infection (Gurley et al., 2014; 
Labrique et al., 2010). For reasons that are unclear, the case-fatality rate is markedly 
elevated (10–40%) in some pregnant women infected with HEV in South Asia, compared to 
the general population (3%) (Hamid et al., 1996; Tsega et al., 1992).
Although the liver is a known target of arsenic carcinogenesis (Liu and Waalkes, 2008) and 
emerging data support arsenic immunotoxicity (Stone, 1969), whether arsenic exposure 
during pregnancy can enhance susceptibility to objectively measured HEV infection during 
pregnancy has not been investigated. The aims of this nested case-control study were to 
assess arsenic exposure during pregnancy and evaluate its association with incident HEV 
seroconversion and changes in cytokine concentrations.
2. Methods
2.1. Study population and assessment of HEV seroconversion
Women in this nested case-control study were participants in a cluster-randomized, 
controlled trial of antenatal multiple micronutrients (15 vitamins and minerals including 
iron-folic acid) at a dietary reference intake (RDA) versus iron-folic acid alone in 
Gaibandha, Bangladesh to assess the impact of antenatal supplementation on infant 
mortality and adverse birth outcomes (West et al., 2013,, 2014). Of the 44,567 pregnancies 
enrolled into the trial, 1526 women from a limited geographic area (−450 km2) contributed a 
blood sample at 1st and 3rd trimester (TM) and 3 months postpartum (PP) as part of a more 
intensive biospecimen sub-study. The samples from the first available 1100 women were 
assessed for incident IgG seroconversion to HEV at the 1st and 3rd TM and 3 months PP 
using a well-characterized National Institutes of Health reference enzyme immunoassay 
(EIA) (Tsarev et al., 1993). The sensitivity of this anti-HEV IgG EIA is 96% and the 
specificity is 98% (Engle et al., 2015; Mast et al., 1998). Among the 1100 women, 39 
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women seroconverted between the 3rd TM and 3 months PP and 1 woman seroconverted to 
HEV between the 1st and 3rd TM. These 40 women (cases) were matched with 40 non-
seroconverting women (controls) by age, parity, and intervention group. All procedures 
were approved by the Johns Hopkins Bloomberg School of Public Health Institutional 
Review Board (IRB 00000570) and the Bangladesh Medical Research Council 
(BMRC/ERC/2007–2010 935) and the trial was registered at ClinicalTrials.gov 
(NCT00860470).
2.2. Urine arsenic analysis
Total arsenic and arsenic species concentrations were measured in spot urine samples of the 
40 HEV seroconverting (cases) and 40 non-seroconverting (controls) women at 1st and 3rd 
TM. The analyses were conducted at the Trace Element Laboratory of the Institute of 
Chemistry-Analytical Chemistry, University of Graz, Austria. All samples were analyzed 
blinded to HEV seroconversion status. The analytical methods used to perform arsenic and 
arsenic species analysis and the associated quality control criteria have been described in 
detail (Scheer et al., 2012). In brief, total arsenic concentrations in urine were measured 
using inductively coupled plasma mass spectrometry (ICPMS) (Agilent 7700x ICPMS, 
Agilent Technologies, Waldbronn, Germany). Arsenic species were measured by high 
performance liquid chromatography (HPLC)-ICPMS (Agilent 1100 HPLC and Agilent 
7700x ICPMS). Urinary arsenic analysis variables were adjusted for urine dilution using 
specific gravity. The method limits of detection were 0.1 µg As/L for all the species. A total 
of 4% of participants were < LOD for arsenobetaine, 7.5% < LOD for inorganic arsenic, and 
0% < LOD for all other arsenic species. In previous population-based studies, the inter-assay 
coefficients of variation for inorganic arsenic, methylarsonic acid (MMA), dimethylarsinic 
acid (DMA) and arsenobetaine plus other arsenic cations in the in-house reference urine 
were 6.0%, 6.5%, 5.9% and 6.5%, respectively (Scheer et al., 2012). The median 
(interquartile range) of arsenobetaine and other arsenic cations was 1.0 (0.6, 1.7) µg As/L 
confirming that seafood intake was relatively low in the population. We used the sum of 
inorganic and methylated arsenic species (∑As) in urine as the biomarker of inorganic 
arsenic exposure. To assess arsenic metabolism, we calculated the relative proportion of 
inorganic and methylated arsenic metabolites in urine to their sum: % inorganic arsenic, % 
MMA and % DMA (Vahter,2000).
2.3. Cytokine analysis
Plasma cytokine measurements have been described in detail elsewhere (Kmush et al., In 
press). In brief, cytokine levels of all HEV seroconverting and non-seroconverting women 
were determined by the electrochemiluminescence-based Meso Scale Discovery (MSD) 
immunoassay in the format of the Human Th1/Th2 10-Plex Ultra-Sensitive Kit for IFN-γ, 
IL-10, IL-12, IL-13, IL-1β, IL-2, IL-4, IL-5, IL-8, and TNF-α according to manufacturer 
protocols (Meso Scale Discovery, Gaithersburg, MD). Plates were read using the SECTOR 
Imager 2400 and data acquired using Discovery Workbench 3.0 software (Meso Scale 
Discovery, Gaithersburg, MD). For all cytokine concentrations below the lower limit of 
detection (LOD), one-half the LOD was imputed. The limit of detection for cytokines was as 
follows: IFN-γ = 0.3 pg/mL, IL-10 = 1.2 pg/mL, IL-12 = 0.7 pg/mL, IL-13 = 3.3 pg/mL, 
IL-1β = 0.5 pg/mL, IL-2 = 0.4 pg/mL, IL-4 = 1.1 pg/mL, IL-5 = 0.1 pg/mL, IL-8 = 0.4 
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pg/mL, and TNF-α = 0.2 pg/mL. We did not include in the analyses the cytokines with 
greater than 20% of samples below the LOD at one or more of the pregnancy time points 
(i.e., IL-1β, IL-4, IL-13).
2.4. Demographic and nutritional factors
Micronutrient measurements have been described in detail elsewhere (West et al., 2014). As 
part of participation in the trial of antenatal multiple micronutrients (West et al., 2014), 
women provided information during their 1st TM about sociodemographic (age, parity, 
gestational age at enrollment, living standards index) and nutritional (food intake) factors. 
Trained anthropometrists measured women's weight, body mass index [BMI], and middle-
upper arm circumference [MUAC]. Information about the season of enrollment (summer, 
rainy, winter) was also collected.
2.5. Statistical analysis
For demographic, nutritional and environmental factors we examined differences using the 
Wilcoxon rank sum test for continuous variables (mean [standard deviation]) and the 
proportion test for categorical and binary variables. Urinary arsenic, arsenic species and 
plasma cytokine data were ln-transformed before analysis. Differences in median 
(interquartile-range [IQR]) urinary arsenic and arsenic species concentrations by HEV 
seroconversion status were assessed by Fisher's exact test of the equality of medians, 
comparing HEV seroconverters to non-seroconverters. We also examined differences in 
urinary arsenic and arsenic species concentrations across pregnancy time points, comparing 
3rd to1st TM using Fisher's exact test of the equality of medians. To visualize median trends 
across 1st and 3rd TM of pregnancy, we plotted the median of urine ∑As concentration 
(µg/L) for each woman and the overall group median trend, by HEV seroconversion status. 
Due to the non-independence of repeated measurements within person, we also examined 
longitudinal associations of changes in mean ∑As concentration (µg/L) across pregnancy 
time points by fitting generalized linear mixed regression models.
Odds ratios and 95% confidence intervals of the urinary arsenic-HEV seroconversion 
association were estimated using conditional logistic regression models. Models were 
adjusted for potential determinants of immune response to infection that could also be 
related to arsenic exposure or metabolism – living standards index, folate, vitamin D, and 
zinc. We used the Fisher's exact test of the equality of medians to assess differences in 
median (IQR) plasma cytokine concentrations by HEV seroconversion status and also 
between adjoining pregnancy time points (1st TM, 3rd TM, 3 months PP) within each 
seroconversion group (i.e., comparing 1st to 3rd TM; comparing 3rd TM to 3 months PP). 
We used generalized linear mixed regression models to estimate the changes in plasma 
cytokine concentrations at 1st and 3rd TM and 3 months PP – included as dependent 
variable in model – for an IQR-unit change in urinary ∑As at 1st and 3rd TM and the 
average of 1st and 3rd TM ∑As (as a measure of average pregnancy arsenic exposure) – 
included as independent variables in separate models – by HEV seroconversion status. 
Multiplicative interaction coding between ∑As and HEV seroconversion status variables 
was used in generalized linear mixed regression models to examine potential effect measure 
modification by HEV seroconversion by comparing a model with interaction terms to a 
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model without using a likelihood ratio test. All analyses were completed using Stata version 
11 (StataCorp LP, College Station, Texas, USA).
3. Results
3.1. Participant characteristics by HEV seroconversion status
HEV seroconverting (cases) and non-seroconverting (controls) women were similar by the 
matching factors (age, parity, and intervention group) as well as other sociodemographic, 
nutritional, anthropometric and pregnancy-related factors (Table 1). There was also no 
difference by season of enrollment over the 4-year period between groups
3.2. Urinary arsenic levels during pregnancy and HEV seroconversion
First TM median and IQR ∑As concentrations in urine were similar among HEV 
seroconverters (median 65.6 µg/L; IQR 40.8, 132.8 µg/L) and non-seroconverters (61.6 
µg/L; 37.0, 82.2 µg/L) (p = 1.0; Table 2). Urinary concentrations of ∑As remained high in 
the 3rd TM among HEV seroconverting women (64.7 µg/L; 26.2, 105.9 µg/L), but declined 
in the 3rd TM among non-seroconverting women (35.9 µg/L; 25.6, 77.4 µg/L) (p = 0.002; 
Table 2; Fig. 1). During the 1st TM of pregnancy, non-seroconverting HEV women had 
higher % DMA (median 80.3%; IQR = 75.6, 82.9%) in urine compared to seroconverting 
women (76.7%; 74.3, 80.5%) (p = 0.003; Table 2).
Increasing urinary arsenic concentration during the 1st TM of pregnancy was associated 
with increasing odds of incident HEV seroconversion. The adjusted odds ratio (95% 
confidence interval [CI]) of incident HEV seroconversion was 2.06 (1.07, 3.97) for every 
IQR-unit increase in 1st TM urinary ∑As concentration (Table 3). A similar association was 
observed for the average of 1st and 3rd TM urinary ∑As concentration (odds ratio 2.17, 95% 
CI 1.07, 4.39) (Table 3). Arsenic methylation profiles were non-statistically significantly 
associated with incident HEV seroconversion. The adjusted odds ratio (95% CI) per IQR-
unit increase in average 1st and 3rd TM % MMA was 1.77 (0.84, 3.74) (Table 3). The 
corresponding odds ratio for % DMA was 0.69 (0.38, 1.25) (Table 3).
3.3. IL-2 and urinary arsenic levels by HEV seroconversion status
The median plasma concentration of IL-2 was 1.73 (IQR 1.22, 2.61), 1.78 (IQR 0.90, 3.28) 
and 2.71 (IQR 1.65, 3.95) pg/mL at 1st TM, 3rd TM and 3 months PP, respectively among 
HEV-seroconverting women and was 1.69 (IQR 0.83, 2.58), 1.75 (IQR 1.05, 2.68) and 1.94 
(IQR 1.51, 2.66) pg/mL at 1st TM, 3rd TM and 3 months PP, respectively among non-
seroconverting women. HEV seroconverting women had higher levels of IL-2 compared to 
non-seroconverting women at 3 months PP (p = 0.04). Among HEV seroconverting women, 
an IQR-unit increase in 1st TM ∑As was associated with a 0.46 pg/mL (95% CI 0.23, 0.68; 
p < 0.0001) increase in plasma IL-2 concentration across the 1st TM, 3rd TM, and 3 months 
PP (Table 4). The corresponding increase in plasma IL-2 concentration across the 3rd TM 
and 3 months PP for an IQR-unit increase in mean 1st and 3rd trimester pregnancy ∑As was 
0.35 pg/mL (95% CI 0.12, 0.58; p < 0.003) among HEV seroconverting women (Table 4). 
Associations of urinary ∑As with IL-2 among non-seroconverting pregnant women were 
around the null (Table 4). We observed evidence of effect measure modification 
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(heterogeneity) of ∑As-IL-2 associations by HEV seroconversion status for 1st TM ∑As (χ2 
(1 df) 5.19, p < 0.02) and average ∑As (χ2 (1 df) 3.25, p < 0.07) (Table 4). Although other 
cytokines varied significantly over time within HEV seroconverters (IFN-γ, TNF-α, and 
IL-5) and non-seroconverters (IL-8 and IL-5) and by HEV seroconversion status (IL-8, 
IL-10, IL-12) (Supplemental Data File Table S1), none showed an association with urinary 
arsenic concentrations within strata of HEV seroconversion status as observed for IL-2 (data 
not shown).
4. Discussion
Results of this study suggest that elevated urinary arsenic levels during pregnancy may be 
related to HEV seroconversion. In the 1st TM, prior to HEV seroconversion, urinary ∑As 
levels were similar between women who later went on to seroconvert to HEV and those who 
did not. By the 3rd TM, however, urinary ∑As levels decreased significantly among non-
seroconverters, while urinary ∑As levels did not decline among HEV seroconverters. Higher 
urinary arsenic levels during early pregnancy and on average across pregnancy were 
associated with incident HEV seroconversion, particularly after adjustment for 
socioeconomic factors and nutritional biomarkers. Although the sample size was relatively 
small, strengths of the study include the prospective design, high quality exposure and 
outcome assessment, adjustment for relevant confounders and the evaluation of immune 
markers.
The biological basis of enhanced susceptibility to HEV seroconversion among women with 
high urinary inorganic arsenic levels during pregnancy is supported by knowledge of arsenic 
hepato- and immunotoxicity. The liver is a primary target site of arsenic metabolism, which 
involves biomethylation through one-carbon metabolism into monomethylated and 
dimethylated arsenic species (Vahter, 2009). As one-carbon metabolism increases during the 
course of pregnancy, the methylation of inorganic arsenic into dimethylated arsenic species 
typically increases, (Gardner et al., 2011) resulting in increased proportion of DMA in urine. 
(Vahter, 2009) DMA is considered a less toxic metabolite than MMA and we found that 
HEV seroconversion was associated with higher % MMA and lower % DMA in urine, 
especially during the 1st TM of pregnancy, although the model estimates were imprecise, 
likely due to the small sample size. The association of higher % MMA and lower % DMA 
with increased risk of disease has been shown for cardiovascular disease and cancer in other 
studies (IARC, 2012; Wu et al., 2014). These results could identify an adverse profile of 
arsenic-related metabolism that is associated with increased risk of HEV seroconversion 
among pregnant women.
Arsenic is known to alter key functions of the innate and adaptive immune system. Arsenic 
has been shown to disturb innate immune responses, including the inhibition of macrophage 
function (Banerjee et al., 2009). Such disturbance of innate immune responses is believed to 
be one potential contributor to the increased frequency of symptoms of respiratory tract 
infections, diarrhea, and fever among arsenic-exposed pregnant women (Kile et al., 2014; 
Raqib et al., 2009). During pregnancy the immune response is associated with a shift to an 
anti-inflammatory or Th2-type response (Chaouat et al., 1997). While beneficial for the 
outcome of pregnancy, reduced inflammatory processes may enhance women's 
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susceptibility to certain infections that require Th1-type immunity for clearance. Th1- and 
Th2-type responses transcriptionally down-regulate each other – a strong Th2-type response 
should reduce a Th1-type response and vice-versa (Lee et al., 2006; Spilianakis and Flavell, 
2007). Research suggests that arsenic exposure may exacerbate anti-inflammatory immune 
responses during pregnancy (Cho et al., 2012), which could further enhance susceptibility to 
infection, particularly viral infections that require Th1-type immune responses for successful 
clearance. It is possible that arsenic exposure during pregnancy may alter Th1-type immune 
responses resulting in susceptibility to seroconversion and viral infection at a lower 
challenge dose of virus than in the absence of arsenic exposure. A compromised immune 
response, increasing morbidity, and higher pulmonary viral titers were observed following a 
sub-lethal influenza virus challenge dose in mice exposed to arsenic relative to arsenic 
unexposed mice (Kozul et al., 2009), but human population-based studies of arsenic 
immunotoxicity and infection among pregnant women are lacking. We could not investigate 
whether arsenic-induced immune alteration is related to symptomatic HEV disease because 
pregnant women in our study did not experience symptomatic HEV disease (as reflected by 
anti-HEV IgG seroconversion without reports of acute viral hepatitis symptoms).
Arsenic is known to impair adaptive immunity. It is recognized that arsenic delays or 
inhibits adaptive T-cell immune response. One mechanism that has been described in detail 
is the delay of T cell proliferation (Soto-Pena and Vega, 2008), and promotion of T cell 
anergy, senescence or tolerance (Soto-Pena et al., 2006) after arsenic exposure. Impairment 
of T cell proliferation has been shown to have adverse effects when an infectious agent 
(such as HEV) is encountered because a delayed or ineffective T-cell response (Galicia et 
al., 2003), combined with ineffective innate immune response, could enhance susceptibility 
to infection. Among the cytokines examined in this study, IL-2, an indicator of immune 
activation, were higher in HEV seroconverters and its levels showed a significant positive 
association with urinary arsenic concentration only among pregnant women who 
seroconverted to HEV, potentially indicating there was activation of the immune response 
by arsenic. IL-2 plays a critical role in initiating the adaptive immune response and T cell 
proliferation. Laboratory studies suggest that after inducing an initial delay in IL-2 
production, arsenic may subsequently induce a “ramping-up” of IL-2 production to achieve 
an effective adaptive immune response (Soto-Pena et al., 2006; Soto-Pena and Vega, 2008). 
This is supportive of a possible role of arsenic exposure in the dynamics of HEV 
seroconversion, and future studies involving functional measures of immune response (e.g., 
immune cell populations, immunoglobulin isotypes) could improve understanding of this 
exposure–response relationship.
Limitations of the study include a small sample size and a lack of assessment of arsenic in 
drinking water and food. However, we measured urine arsenic, which is a well-established 
biomarker that integrates all sources of arsenic exposure (including drinking water and 
food). The observed differences in urinary arsenic levels were unlikely due to changes to an 
alternative water supply because sources of drinking water in the study area remained 
constant, nor was it likely due to differences in hydration status since all analyses were 
adjusted for urine dilution via specific gravity. Future studies should measure arsenic and 
pathogens in water and food and assess urinary arsenic levels during the postpartum period 
to address these limitations.
Heaney et al. Page 8
Environ Res. Author manuscript; available in PMC 2016 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Despite the small sample size, important strengths of the study include use of a prospective 
design, nested within a large cohort, objective measures of arsenic exposure in urine, 
objective assessment of outcome (incident seroconversion) for a pathogen that causes a 
significant burden of morbidity and mortality in pregnancy (HEV), measurement of pro- and 
anti-inflammatory cytokines in plasma, the inclusion of objectively measured micronutrients 
as confounders, and the availability of repeated measurements during pregnancy and 
postpartum. These strengths represent an improvement on previous studies of arsenic 
exposure and infection during pregnancy because most involved classification of exposures 
or outcomes via participant self-reports of symptoms (Kile et al., 2014; Raqib et al., 2009). 
Anti-HEV IgG seroconversion constitutes incident HEV infection; however, pregnant 
women who seroconverted to HEV in our study did not report symptoms of acute HEV 
disease – e.g., none reported icterus, fever, clay-colored stools during the follow-up period. 
Our findings may therefore provide important insights into the dynamics of arsenic exposure 
with early sentinel immune responses and asymptomatic infection and could inform novel 
hypotheses for future research of symptomatic HEV infection during pregnancy in 
population-based and clinical settings.
The possibility of reverse causation should be considered. Pregnant women who 
seroconverted to HEV may have experienced a cascade of events related to viral 
seroconversion that could have led to reduced metabolism of arsenic in the liver and thus 
resulted in higher unmethylated arsenic, which has a longer half-life than methylated arsenic 
species, and then higher urinary ∑As levels. To address this question, future studies should 
study the relation of arsenic exposure among pregnant women with symptomatic HEV 
disease because this may reflect dynamics of more severe metabolic stress on the liver than 
among asymptomatic HEV infections observed in our study. The small sample size 
precluded a more extensive analysis of confounding and/or effect measure modification. 
Micronutrients included in our analysis were those known to influence one-carbon 
metabolism and arsenic metabolism (folate) (Gamble et al., 2006) and those hypothesized to 
be associated with immune response (zinc, vitamin D) (Bartley,2010; Mahalanabis et al., 
2004). However, given that all women in this nested case-control study received antenatal 
multiple micronutrients at a daily requirement level or the same level of iron-folic acid alone 
as part of an intervention trial, future studies should be conducted among women not 
receiving micronutrient supplements in order to assess the potential impact of micronutrient 
deficiency status on arsenic exposure, infection, and immune response.
5. Conclusions
Our findings contribute to understanding arsenic immunotoxic effects during pregnancy and 
postpartum. In Bangladesh, a large proportion of the population relies on water from tube 
wells that are contaminated with arsenic (Karagas, 2010). In Bangladesh and other areas 
where genotype 1 HEV is endemic, transmission occurs via the fecal-oral route principally 
via fecally-contaminated surface water. During pregnancy, it may be important to consider 
the context of exposure to arsenic and HEV (as well as other pathogens related to water, 
hygiene, and sanitation conditions). In rural Bangladesh, near the location of the present 
study, HEV seroprevalence estimates range between 20% and 23% (Labrique et al., 2010) 
and have been observed as high as 40–80% in other areas of Bangladesh (Mahtab et al., 
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2009). With such high HEV endemicity and co-occurring arsenic exposure, if the 
associations we observed are causal, the population at risk could be large. A more complete 
understanding of the effects of arsenic on immune alterations and other infectious diseases 
during pregnancy could inform interventions to reduce morbidity and mortality where 
exposure to pathogenic and immunotoxic agents co-exists.
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Fig. 1. 
Trends of inorganic arsenic plus methylated species (∑As) concentration (µg/L) in urine 
during the 1st and 3rd trimester (TM) of pregnancy among: A. HEV seroconverting (n = 40) 
and B. non-seroconverting (n = 39) women. Gray lines depict individual trajectories for each 
pregnant woman and the black line denotes the median trajectory within each group. Note. 
The p-value shown compares 1st and 3rd TM urinary ∑As derived from Fisher's exact test of 
the equality of medians. The beta (standard error), p-value from a linear mixed model of the 
temporal association between trimester (3rd vs 1st) and ln-transformed ∑As concentration 
(µg/L) was −0.27 (0.13), p < 0.04 among HEV seroconverters and −0.34 (0.11), p < 0.003 
among non-seroconverters.
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Table 1
Participant characteristics at 1st trimester of pregnancy by HEV seroconversion status.
HEV
seroconverters
Non-
seroconverter
pa
N 40 40
Age (years) 22.1 (4.7) 22.1 (4.6) 1
Parity 0.9 (0.91) 0.9 (0.92) 1
Gestational age at enrollment (weeks) 10.1 (3.3) 11.5 (5.1) 0.23
Weight (kg) 43.0 (8.2) 44.0 (6.5) 0.52
Height (cm) 148.9 (4.8) 148.7 (4.9) 0.94
BMI (kg/m2) 19.3 (3.4) 19.9 (2.5) 0.17
BMI < 18.5 (%) 43 25 0.10
MUAC (cm) 23.4 (3.0) 24.3 (3.4) 0.21
MUAC ≤ 22.5 cm (%) 35 23 0.22
Plasma
  Folate (nmol/L) 21.1 (8.0) 20.5 (9.7) 0.68
  Vitamin D (nmol/L) 39.8 (6.0) 41.0 (11.3) 0.57
  Zinc (µmol/L) 11.5 (2.0) 12.5 (2.3) 0.04
  Living standards index 0.04 (1.05) 0.09 (1.13) 0.93
Season (%)
  Summer 25 28 0.80
  Rainy 55 48 0.50
  Winter 20 25 0.59
Note. Data are mean (standard deviation) or %. Participants were matched on age, parity and nutritional intervention. BMI = body mass index. 
MUAC = middle-upper arm circumference. Summer consists of January to May; Rainy of June to August; and Winter of September to December.
a
p derived from Wilcoxon rank-sum test for continuous variables, proportion test for categorical and binary variables.
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